Canine Recurrent Bacterial Cystitis: Clinical Decisions

Bottom line

Recurrent canine bacterial cystitis requires confirmation of symptomatic infection and investigation of why episodes recur. ISCAID distinguishes reinfection from persistent or relapsing infection and discourages repeated antimicrobial prescribing without an underlying-cause assessment. [1] The immediate question is whether the dog has bacterial clinical disease now, not whether another culture can be made negative.

Separate a symptomatic episode from bacteriuria

Lower urinary tract signs, urinalysis and culture must be interpreted together. ISCAID defines subclinical bacteriuria as a positive culture from an appropriately collected sample without clinical evidence of infectious urinary disease. Neither bacterial colony count nor pyuria alone distinguishes this from cystitis. [1]

Record the actual episode: dysuria, frequency, hematuria, discomfort, continence changes and what the caregiver could observe. In a neurologically impaired patient, the ability to show typical signs may be limited. Do not substitute urine odor or an isolated laboratory flag for the clinical assessment.

The canine protein-losing nephropathy workflow addresses a different renal question. Urinary protein is not a diagnosis of bacterial infection, and a renal-disease label should not make every positive culture a treatment indication.

Reconstruct the recurrence pattern before changing drugs

Obtain previous culture reports, sample methods, susceptibility results, treatment exposure and the interval between clinical episodes. ISCAID recommends culture in recurrent cystitis, preferably from cystocentesis, and review of the drug, regimen, susceptibility interpretation and actual medication delivery when response has been incomplete. A different recovered organism makes reinfection more likely; persistent or relapsing disease prompts investigation for a nidus or inadequate delivery. [1]

Keep suspected patterns provisional when earlier cultures are missing. A remembered “same infection” is not equivalent to comparative laboratory data, and the same reported species does not by itself document strain identity. Ask what the new culture is expected to change before sampling during or after treatment.

Find the predisposing problem rather than prescribing indefinitely

ISCAID emphasizes identifying relevant comorbidities and structural or functional abnormalities. Imaging or cystoscopy may be appropriate for refractory cases; targeted bladder tissue sampling can be considered when signs persist despite negative urine cultures. Repeated antibiotics alone are unlikely to provide durable control when the underlying problem remains. [1]

Review voiding function, continence, genital and perineal findings, uroliths, prior urinary procedures and systemic disease. In a male dog, clarify whether prostatic disease is a separate concern. State which suspected factor is actionable and whether referral would change the diagnostic options.

The amoxicillin-clavulanate reference covers that drug's indication and stewardship questions. A previous response to one product does not settle the present organism, site of infection or need for another course.

Select treatment around clinical disease and site

Recurrent cystitis is not an automatic indication for a prolonged course. ISCAID allows different approaches for reinfection versus persistent or relapsing disease and emphasizes clinical cure with minimal adverse effects and resistance selection. If empirical treatment is needed, reassess it when culture and the patient's response are available. [1]

Suspected pyelonephritis or prostatitis changes drug selection because tissue exposure matters rather than urinary concentration alone. ISCAID specifically separates those syndromes from bladder infection. [1] Do not apply a urinary susceptibility interpretation or a bladder-directed agent to a tissue infection without checking the relevant site and breakpoints.

Specify the review point, intended clinical response and action if the course diverges. A nonresponding dog needs reassessment of the diagnosis, sampling, administration and anatomical problem before an unexamined change to broader therapy.

Interpret follow-up cultures without treating the laboratory alone

ISCAID notes that a post-treatment culture after clinical recovery can assist investigation of relapse, persistence or reinfection, but is not itself a reason to prescribe. Routine treatment of subclinical bacteriuria is discouraged; pyuria or multidrug resistance alone does not change that principle. Selected high-risk situations require individual judgment, and supporting evidence is limited. [1]

Document why a clinically well dog was tested and what consequence was planned for a positive result. If signs recur, obtain an episode-specific assessment rather than continuing an asymptomatic surveillance-and-treatment cycle. Keep concern for an upper-tract or systemic infection separate from uncomplicated culture positivity.

Discuss prevention evidence at its actual level

A small study compared cranberry extract with an antimicrobial in dogs with a history of recurrent UTI. No dog in either group developed UTI; a separate laboratory component found reduced bacterial adhesion. Those results do not establish clinical equivalence to antimicrobial treatment or benefit over an untreated comparison. [2]

A randomized placebo-controlled trial in dogs recovering from acute thoracolumbar disc surgery did not demonstrate reduced bacteriuria with cranberry extract. It had limited power, and its postoperative neurological population and bacteriuria endpoint differ from symptomatic recurrent cystitis in otherwise ambulatory dogs. [3]

ISCAID does not recommend routine antimicrobial prophylaxis and considers evidence for cranberry and other alternative preventive therapies insufficient. [1] Put correction of the identified predisposing problem and a practical plan for genuine clinical recurrence ahead of a supplement or indefinite prescription.

Frequently Asked Questions

Does a positive urine culture automatically mean recurrent bacterial cystitis?

No. Compatible clinical disease must be distinguished from subclinical bacteriuria, which is defined by culture-positive urine without clinical evidence of infectious urinary disease. [1]

Should recurrent symptomatic episodes be cultured?

Yes. ISCAID recommends urine culture, ideally from a cystocentesis specimen, in recurrent cystitis. [1]

Does recurrent disease automatically require prolonged antibiotics?

No. ISCAID distinguishes reinfection from persistent or relapsing disease and does not automatically recommend long-term treatment, even with a comorbidity. [1]

Must every positive post-treatment culture trigger another prescription?

No. After clinical recovery, a positive culture can help investigate recurrence patterns but should be assessed as possible subclinical bacteriuria rather than an automatic treatment indication. [1]

Does multidrug resistance alone justify treating subclinical bacteriuria?

No. ISCAID states that resistance alone should not change the decision whether subclinical bacteriuria needs treatment. [1]

Did the small recurrent-UTI cranberry study prove equivalence to antibiotics?

No. No dog developed UTI in either comparison group, but the small active-comparator study did not establish clinical equivalence or benefit versus no intervention. [2]

Did the placebo-controlled spinal-injury trial demonstrate cranberry benefit?

No. It did not demonstrate a reduction in bacteriuria in dogs recovering from thoracolumbar disc surgery; power and population limits prevent a universal conclusion about every recurrent-cystitis patient. [3]